Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan

Kunsulu Zakarya; Lespek Kutumbetov; Mukhit Orynbayev; Yergali Abduraimov; Kulyaisan Sultankulova; Markhabat Kassenov; Gulbanu Sarsenbayeva; Ilyas Kulmagambetov; Timur Davlyatshin; Maria Sergeeva; Marina Stukova; Berik Khairullin

eClinicalMedicine (2021) - Comments
pubmed: 34414368 doi: 10.1016/j.eclinm.2021.101078 issn: 2589-5370

Kunsulu Zakarya, Lespek Kutumbetov, Mukhit Orynbayev, Yergali Abduraimov, Kulyaisan Sultankulova, Markhabat Kassenov, Gulbanu Sarsenbayeva, Ilyas Kulmagambetov, Timur Davlyatshin, Maria Sergeeva, Marina Stukova, Berik Khairullin